Biopharmaceutical Consultant
Internal Medicine
Dr. Orville G. Kolterman, MD
|
|
Give Review
Orville Kolterman practices Internal Medicine. He went to Stanford University School of Medicine. Stanford University School of Medicine is a top medical college. Stanford University School of Medicine has a rank of 2 in research and a 25 in primary care Orville Kolterman is a published MD as well. He has 100 publications published. The latest was: Pramlintide, a synthetic analog of human amylin, improves the metabolic profile of patients with type 2 diabetes using insulin. The Pramlintide in Type 2 Diabetes Group.
Publications
- Pramlintide improved measures of glycemic control and body weight in patients with type 1 Diabetes mellitus undergoing continuous subcutaneous insulin infusion therapy.
- Properties of pramlintide and insulin upon mixing.
- Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 Diabetes mellitus.
- Effect of pramlintide on weight in overweight and obese insulin-treated type 2 Diabetes patients.
- Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 Diabetes: a dose-timing study.
- Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 Diabetes.
- Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 Diabetes: a 1-year randomized controlled trial.
- Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 Diabetes intensively treated w...
- A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 Diabetes.
- Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 Diabetes.
- Recovery and hypersecretion of insulin and reversal of insulin resistance after withdrawal of short-term cyclosporine treatment.
- The effect of ten days of fasting on various aspects of carbohydrate metabolism in obese diabetic subjects with significant fasting hyperglycemia.
- Defect in glucose removal in nonketotic diabetic patients with fasting hyperglycemia.
- Inhibition of insulin release by cyclosporine and production of peripheral insulin resistance in the dog.
- Insulin resistance and Diabetes due to different mutations in the tyrosine kinase domain of both insulin receptor gene alleles.
- Computerized ambulatory-care pharmacy information system for direct order entry by prescribers.
- Non-insulin-mediated glucose uptake predominates in postabsorptive dogs.
- Selective suppression of hepatic glucose output by human proinsulin in the dog.
- The metabolic effects of biosynthetic human proinsulin in individuals with type I Diabetes.
- Biosynthetic human insulin and proinsulin have additive but not synergistic effects on total body glucose disposal.
- Insulin binding in human pregnancy: comparisons to the postpartum, luteal, and follicular states.
- Continuous subcutaneous insulin infusion in an obese insulin-resistant pregnant woman with type II Diabetes: accelerated fetal growth and neonatal complications.
- Mechanism of hypertriglyceridaemia in diabetic patients with fasting hyperglycaemia.
- Diabetes due to secretion of an abnormal insulin.
- Effect of race and hypertension on plasma amylin concentrations.
- The effects of biosynthetic human proinsulin on carbohydrate metabolism.
- A structurally abnormal insulin causing human Diabetes.
- Modulation of gastric emptying as a therapeutic approach to glycaemic control.
- Amylin innocent in essential hypertension?
- The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 Diabetes mellitus.
- Effect of pramlintide on A1C and body weight in insulin-treated African Americans and Hispanics with type 2 Diabetes: a pooled post hoc analysis.
- Addition of pramlintide to insulin therapy lowers HbA1c in conjunction with weight loss in patients with type 2 Diabetes approaching glycaemic targets.
- Effect of pramlintide on symptom, catecholamine, and glucagon responses to hypoglycemia in healthy subjects.
- Metabolic effects of the incretin mimetic exenatide in the treatment of type 2 Diabetes.
- Effect of adjunctive pramlintide treatment on treatment satisfaction in patients with type 1 Diabetes.
- A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 Diabetes.
- Pramlintide improved glycemic control and reduced weight in patients with type 2 Diabetes using basal insulin.
- Is pramlintide a safe and effective adjunct therapy for patients with type 1 Diabetes?
- Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 Diabetes: a dose-timing study.
- Type II Diabetes: who has the keys?
- Reduction of postprandial hyperglycemia in subjects with IDDM by intravenous infusion of AC137, a human amylin analogue.
- Low-carbohydrate diet alters intracellular glucose metabolism but not overall glucose disposal in exercise-trained subjects.
- Receptor and postreceptor defects contribute to the insulin resistance in noninsulin-dependent Diabetes mellitus.
- Comparison of the metabolic responses to fructose and sucrose sweetened foods.
- Insulin action and resistance in obesity and noninsulin-dependent type II Diabetes mellitus.
- Insulin resistance and Diabetes due to a genetic defect in insulin receptors.
- Mechanism of the postreceptor defect in insulin action in human obesity. Decrease in glucose transport system activity.
- The effect of short-term alpha-glucosidase inhibition on carbohydrate and lipid metabolism in Type II (noninsulin-dependent) diabetics.
- The impact of sulfonylureas on hepatic glucose metabolism in Type II diabetics.
- Metabolic consequence of two-week fructose feeding in diabetic subjects.
- In vivo deactivation of proinsulin action on glucose disposal and hepatic glucose production in normal man.
- Metabolic consequences of very-low-calorie diet therapy in obese non-insulin-dependent diabetic and nondiabetic subjects.
- Antiinsulin receptor antibodies in an insulin-dependent diabetic may arise as autoantiidioTypes.
- Day-long integrated serum insulin and C-peptide profiles in patients with NIDDM. Correlation with urinary C-peptide excretion.
- Adipocyte glycogen synthase and pyruvate dehydrogenase in obese and Type II diabetic subjects.
- Correlation of in vivo and in vitro actions of insulin in obesity and noninsulin-dependent Diabetes mellitus: role of the glucose transport system.
- Effects of insulin infusion on human skeletal muscle pyruvate dehydrogenase, phosphofructokinase, and glycogen synthase. Evidence for their role in oxidative and nonox...
- Comparison of serum glucose, insulin, and glucagon responses to different Types of complex carbohydrate in noninsulin-dependent diabetic patients.
- Mechanisms of insulin resistance in obesity and noninsulin-dependent (type II) Diabetes.
- Effects of oral fructose in normal, diabetic, and impaired glucose tolerance subjects.
- Mechanisms of insulin resistance in human obesity: evidence for receptor and postreceptor defects.
- Postprandial hormonal responses to different Types of complex carbohydrate in individuals with impaired glucose tolerance.
- A defect in cell-mediated immune function in insulin-resistant diabetic and obese subjects.
- Short-term regulation of insulin receptor affinity in man.
- The effects of oral fructose, sucrose, and glucose in subjects with reactive hypoglycemia.
- In vivo deactivation of peripheral, hepatic, and pancreatic insulin action in man.
- Insulin treatment reverses the insulin resistance of type II Diabetes mellitus.
- Role of glucose transport in the postreceptor defect of non-insulin-dependent Diabetes mellitus.
- Insulin resistance in non-insulin-dependent, type II Diabetes mellitus.
- The role of the glucose transport system in the postreceptor defect in insulin action associated with human aging.
- The acute and chronic effects of sulfonylurea therapy in Type II diabetic subjects.
- Insulin resistance in noninsulin-dependent Diabetes mellitus: impact of sulfonylurea agents in vivo and in vitro.
- The physiological significance of the glucose intolerance of aging.
- The metabolic effects of 2-week fructose feeding in normal subjects.
- Influence of hyperglycemia on insulin's in vivo effects in type II Diabetes.
- Lack of in vivo insulin resistance in controlled insulin-dependent, Type I, diabetic patients.
- Insulin receptors in isolated human adipocytes. Characterization by photoaffinity labeling and evidence for internalization and cellular processing.
- Mechanisms of insulin resistance in aging.
- Relationship between serum glucose level and the metabolic clearance rate of glucose in non-insulin-dependent Diabetes mellitus.
- Insulin treatment reverses the postreceptor defect in adipocyte 3-O-methylglucose transport in type II Diabetes mellitus.
- Acquired Type 3 hyperlipoproteinemia. Report of three cases associated with systemic lupus erythematosus and diabetic ketoacidosis.
- Adrenocortical steroid treatment of rheumatic diseases. Effects on lipid metabolism.
- Ultrastructural and physiological evidence for corticosteroid-induced alterations in hepatic production of very low density lipoprotein particles.
- Longitudinal evaluation of the effects of sulfonylurea therapy in subjects with type II Diabetes mellitus.
- Mechanisms of insulin resistance in non-insulin-dependent (type II) Diabetes.
- Insulin resistance in non-insulin dependent (type II) and insulin dependent (type I) Diabetes mellitus.
- Modulation of insulin secretion by insulin and glucose in type II Diabetes mellitus.
- The metabolic clearance of insulin and the feedback inhibition of insulin secretion are altered with aging.
- The effect of insulin treatment on insulin secretion and insulin action in type II Diabetes mellitus.
- Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in Type II diabetics.
- Rates of noninsulin-mediated glucose uptake are elevated in Type II diabetic subjects.
- Decreased activation of skeletal muscle glycogen synthase by mixed-meal ingestion in NIDDM.
- Elevated insulin, norepinephrine, and neuropeptide Y in hypertension.
- Glyburide in non-insulin-dependent Diabetes: an update.
- Effect of a high carbohydrate diet on insulin binding to adipocytes and on insulin action in vivo in man.
- Insulin-stimulated glucose transport in human adipocytes.
- The effects of acute and chronic starvation on insulin binding to isolated human adipocytes.
- Relationship between in vivo insulin resistance and decreased insulin receptors in obese man.
- Pramlintide, a synthetic analog of human amylin, improves the metabolic profile of patients with type 2 Diabetes using insulin. The Pramlintide in Type 2 Diabetes Group.
Schools
Stanford University
University Chicago Hosps Clins
Stanford
Conditions Treated
- Diabetes Type 1
- Diabetes Type 2
- Hyperlipidemia
Doctors Specialties
- Internal Medicine
Accepted Insurances
Education
-
University of Chicago -
Stanford University School of Medicine